II. Indications
- See First Generation Cephalosporin
-
Generic and similar efficacy to Cephalexin
- Ease of twice daily dosing instead of four times daily
- Specific Indications
- Skin and Soft Tissue Infection
- Streptococcal Pharyngitis
- Simple Urinary Tract Infections (Acute Cystitis)
- Not indicated for Otitis Media (inadequate coverage due to resistance)
III. Mechanism
IV. Dosing
- May take with or without food
- Adult
- Give 1 g orally twice daily
- May decrease to 500 mg orally twice daily in simple UTI and Streptococcal Pharyngitis
- Child (age > 6 weeks)
- Give 30 mg/kg/day orally divided twice daily
-
Renal Dosing (Adult)
- eGFR 26 to 50 ml/min
- First dose 1 gram orally
- Then 500 mg orally every 12 hours
- eGFR 11 to 25 ml/min
- Take 500 mg every 24 hours
- eGFR <10 ml/min
- Take 500 mg every 36 hours
- eGFR 26 to 50 ml/min
V. Adverse Effects
-
Allergic Reaction
- Cross reactivity with Amoxicillin
VI. Safety
- Pregnancy Category B (All Trimesters)
- Safe in Lactation
VII. Resources
VIII. References
- (2012) Presc Lett, Resource #280706, Comparison of Cephalosporins
Images: Related links to external sites (from Bing)
Related Studies
cefadroxil (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
CEFADROXIL 1 GM TABLET | Generic | $2.73 each |
CEFADROXIL 250 MG/5 ML SUSP | Generic | $0.21 per ml |
CEFADROXIL 500 MG CAPSULE | Generic | $0.27 each |
CEFADROXIL 500 MG/5 ML SUSP | Generic | $0.30 per ml |
Ontology: Cefadroxil (C0007538)
Definition (NCI) | A semi-synthetic, beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cefadroxil binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. |
Definition (MSH) | Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative. |
Concepts | Antibiotic (T195) , Organic Chemical (T109) |
MSH | D002434 |
SnomedCT | 13414000, 372651006 |
LNC | LP17101-4, MTHU005578 |
English | 4 Hydroxycephalexin, 4-Hydroxycephalexin, Cefadroxil, Cephadroxyl, 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-, (6R,7R)-7-(((2R)-Amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, cefadroxil, CEFADROXIL, Cefadroxil [Chemical/Ingredient], cephadroxyl, Cefadroxil Monohydrate, Cefadroxil (product), Cefadroxil (substance) |
Swedish | Cefadroxil |
Czech | cefadroxil |
Finnish | Kefadroksiili |
Italian | 4-Idrossi cefalessina, Cefadrossil |
Russian | TSEFADROKSIL, ЦЕФАДРОКСИЛ |
Japanese | セファドロキシル |
Polish | Cefadroksyl |
Spanish | cefadroxilo (producto), cefadroxilo (sustancia), cefadroxilo, Cefadroxilo |
French | Céfadroxil |
German | Cefadroxil |
Portuguese | Cefadroxila |
Ontology: Duricef (C0701890)
Concepts | Antibiotic (T195) , Organic Chemical (T109) |
MSH | D002434 |
English | duricef, Duricef |